- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 5,348
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Metastases
- Interventions
- Stereotactic Radiosurgery, Surgical Resection, Magnetic Resonance Imaging
- Device · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pulmonary Hypertension
- Interventions
- sitaxsentan sodium
- Drug
- Lead sponsor
- ICOS-Texas Biotechnology
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Francisco, California • Torrance, California + 21 more
- Conditions
- Lymphoma
- Interventions
- ACTR707, rituximab
- Biological
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • New Haven, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- celecoxib, Ibuprofen, Naproxen
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 871
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
- Conditions
- Crohn's Disease, IBD
- Interventions
- Infliximab, Adalimumab
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 22 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Macitentan, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
- Conditions
- Aortoiliac Aneurysms, Iliac Aneurysms
- Interventions
- Zenith® Branch Endovascular Graft-Iliac Bifurcation,
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Palo Alto, California • Stanford, California + 20 more
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
- Interventions
- Standard of Care Referral, Low Threshold Buprenorphine
- Other · Behavioral
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Baton Rouge, Louisiana + 5 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Axatilimab, Ruxolitinib, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Ivosidenib, Ruxolitinib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Milwaukee, Wisconsin
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin glargine, insulin degludec, metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 18
- States / cities
- Inglewood, California • Los Angeles, California • Redlands, California + 14 more
- Conditions
- Keratitis, Corneal Ulcer
- Interventions
- Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
- Combination Product · Other
- Lead sponsor
- Peschke GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
- Conditions
- Hearing Loss
- Interventions
- Not listed
- Lead sponsor
- Med-El Corporation
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Durham, North Carolina • Nashville, Tennessee + 2 more
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo, Hydrochlorothiazide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Anaheim, California • Lomita, California • Miami, Florida + 5 more
- Conditions
- Hemophilia A, Congenital
- Interventions
- Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Male only
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ECTEINASCIDIN 743
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab, Dexamethasone, Venetoclax
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Rochester, Minnesota • Wauwatosa, Wisconsin
- Conditions
- Parkinson's Disease
- Interventions
- Inosine, Placebo
- Drug
- Lead sponsor
- Michael Alan Schwarzschild
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Head and Neck Cancer
- Interventions
- filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
- Conditions
- Head and Neck Cancer
- Interventions
- perifosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
- Conditions
- Cardiovascular Diseases
- Interventions
- AngioDefender, Ultrasound
- Device
- Lead sponsor
- Everist Genomics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boulder, Colorado • Derby, Connecticut • Boston, Massachusetts + 1 more
- Conditions
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 26
- States / cities
- Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more